Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT04256473

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04256473
Other papers using this trial's data
  • Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke: A Randomized Clinical Trial JAMA neurology, 2023-07-01 DOI, PubMed 37213122, PMC10203964 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04256473. Randomized; single masking; primary purpose treatment. Start 2019-08-10 (actual); primary completion 2022-03-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
Acronym
DUMAS
Intervention (Drug)
mutant pro-urokinase
Intervention (Drug)
Alteplase
Lead sponsor
Erasmus Medical Center (class: other)
Collaborator
DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution. (class: not stated)

Record details

Record id
cardio:ct-nct04256473
Content hash
68393cd1e8ab1381a7797c729fd9f66cc9ec7080bdeeaa026907e7bb1774975f